Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

ConclusionErenumab was associated with clinically relevant improvements in all efficacy endpoints and was well tolerated across all subgroups of Japanese migraine patients with/without prior preventive treatment failure(s) and with/without concomitant preventive treatment.Trial registrationClinicaltrials.gov. NCT03812224. Registered January 23, 2019.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research